Body mass index and venetoclax-hypomethylating agent induction therapy for acute myeloid leukemia. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include ...
In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a ...
BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, ...
NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a ...
A new study has unveiled when chronic myeloid leukaemia, a type of cancer that affects the blood and bone marrow, arises in life and how fast it grows. Researchers reveal explosive growth rates of ...
NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be presenting at ASH the findings of a joint study conducted with scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback